Alnylam Pharmaceuticals, Inc. (ALNY)Healthcare | Biotechnology | Cambridge, United States | NasdaqGS
279.84 USD
-8.23
(-2.855%) ⇩
(July 14, 2026, 10:03 a.m.
EDT)
|
Hot Take ↕ | July 11, 2026, 5:29 a.m. EDT
Alnylam offers a strong long-term investment case anchored by exceptional fundamentals, including nearly 100 percent revenue growth and a return on equity exceeding 90 percent, which aligns with the criteria for a high-conviction buy. The balance sheet is fortified with cash covering debt, though the high trailing valuation multiple warrants caution. Short-term momentum is constructive as the stock trades above its fifty-day average, yet the statistical forecast suggests minor near-term downside pressure, keeping the near-term rating slightly below maximum potential. There is no dividend yield available, resulting in a zero rating for income investors. Options activity shows mixed sentiment with bullish call positioning offset by defensive put buying, indicating a volatile path ahead. |
| Model | MAE |
|---|---|
| MSTL_90_126 ✓ | 0.064048 |
| MSTL_90 | 0.098703 |
| MSTL_126 | 0.119073 |
| AutoETS | 0.127240 |
| AutoARIMA | 0.127242 |
| MSTL | 0.133787 |
| AutoTheta | 0.139581 |
Forecast horizon: 60 days | Selected: MSTL_90_126
| Forecast Reliability | |
|---|---|
| Score | 44% |
| H-stat | 1.85 |
| Ljung-Box p | 0.000 |
| Jarque-Bera p | 0.764 |
| Excess Kurtosis | -0.33 |
| Attribute | Value |
|---|---|
| Sector | Healthcare |
| Debt to Equity Ratio | 276.203 |
| Revenue per Share | 32.524 |
| Market Cap | 37,361,491,968 |
| Trailing P/E | 70.31 |
| Forward P/E | 20.77 |
| Beta | 0.27 |
| Profit Margins | 12.55% |
| Website | https://www.alnylam.com |
As of July 11, 2026, 5:29 a.m. EDT: Speculators are positioning for continued upside with heavy open interest in out-of-the-money calls at strikes like 340 and 420, suggesting a bullish bias. However, significant put volume exists at lower strikes (250-300), indicating hedging or a floor expectation. Implied volatility remains elevated, reflecting uncertainty around the recent price surge.
| Attribute | Value |
|---|---|
| 52 Week Change | -0.07411933 |
| Address1 | 675 West Kendall Street |
| Address2 | Henri A. Termeer Square |
| All Time High | 495.55 |
| All Time Low | 3.65 |
| Ask | 282.03 |
| Ask Size | 1 |
| Audit Risk | 4 |
| Average Analyst Rating | 1.8 - Buy |
| Average Daily Volume10 Day | 1,879,740 |
| Average Daily Volume3 Month | 1,260,319 |
| Average Volume | 1,260,319 |
| Average Volume10Days | 1,879,740 |
| Beta | 0.269 |
| Bid | 279.0 |
| Bid Size | 1 |
| Board Risk | 2 |
| Book Value | 8.059 |
| City | Cambridge |
| Compensation As Of Epoch Date | 1,767,139,200 |
| Compensation Risk | 5 |
| Country | United States |
| Crypto Tradeable | 0 |
| Currency | USD |
| Current Price | 279.835 |
| Current Ratio | 3.127 |
| Custom Price Alert Confidence | HIGH |
| Date Short Interest | 1,782,777,600 |
| Day High | 286.755 |
| Day Low | 279.49 |
| Debt To Equity | 276.203 |
| Display Name | Alnylam Pharmaceuticals |
| Earnings Call Timestamp End | 1,777,552,200 |
| Earnings Call Timestamp Start | 1,777,552,200 |
| Earnings Timestamp | 1,777,552,200 |
| Earnings Timestamp End | 1,785,414,600 |
| Earnings Timestamp Start | 1,785,414,600 |
| Ebitda | 806,942,976 |
| Ebitda Margins | 0.18823 |
| Enterprise To Ebitda | 47.613 |
| Enterprise To Revenue | 8.962 |
| Enterprise Value | 38,420,639,744 |
| Eps Current Year | 9.37311 |
| Eps Forward | 13.47404 |
| Eps Trailing Twelve Months | 3.98 |
| Esg Populated | 0 |
| Exchange | NMS |
| Exchange Data Delayed By | 0 |
| Exchange Timezone Name | America/New_York |
| Exchange Timezone Short Name | EDT |
| Fax | 617 551 8101 |
| Fifty Day Average | 296.1466 |
| Fifty Day Average Change | -16.311615 |
| Fifty Day Average Change Percent | -0.055079527 |
| Fifty Two Week Change Percent | -7.411933 |
| Fifty Two Week High | 495.55 |
| Fifty Two Week High Change | -215.715 |
| Fifty Two Week High Change Percent | -0.43530422 |
| Fifty Two Week Low | 273.11 |
| Fifty Two Week Low Change | 6.725006 |
| Fifty Two Week Low Change Percent | 0.024623802 |
| Fifty Two Week Range | 273.11 - 495.55 |
| Financial Currency | USD |
| First Trade Date Milliseconds | 1,086,096,600,000 |
| Float Shares | 132,941,139 |
| Forward Eps | 13.47404 |
| Forward P E | 20.768456 |
| Free Cashflow | 204,714,128 |
| Full Exchange Name | NasdaqGS |
| Full Time Employees | 2,500 |
| Gmt Off Set Milliseconds | -14,400,000 |
| Governance Epoch Date | 1,782,864,000 |
| Gross Margins | 0.80827004 |
| Gross Profits | 3,464,971,008 |
| Has Pre Post Market Data | 1 |
| Held Percent Insiders | 0.00184 |
| Held Percent Institutions | 1.0202 |
| Implied Shares Outstanding | 133,512,573 |
| Industry | Biotechnology |
| Industry Disp | Biotechnology |
| Industry Key | biotechnology |
| Is Earnings Date Estimate | 1 |
| Language | en-US |
| Last Fiscal Year End | 1,767,139,200 |
| Long Business Summary | Alnylam Pharmaceuticals, Inc. discovers, develops, manufactures, and commercializes therapeutics based on ribonucleic acid interference in the United States, Europe, and internationally. The company offers ONPATTRO for hereditary transthyretin-mediated (hATTR) amyloidosis; AMVUTTRA for ATTR and hATTR amyloidosis; Leqvio for hypercholesterolemia; Qfitlia for hemophilia A or B; GIVLAARI for acute hepatic porphyria; and OXLUMO for primary hyperoxaluria type 1. It also develops a range of products in Phase 3 trial, such as Nucresiran for ATTR amyloidosis; Zilebesiran for hypertension; Cemdisiran for myasthenia gravis, paroxysmal nocturnal hemoglobinuria, and geographic atrophy; and Elebsiran for hepatitis D virus infections. In addition, the company is developing various products in Phase 2 trial, including Rapirosiran for metabolic dysfunction-associated steatohepatitis; ALN-ANG3 for diabetic kidney disease; ALN-4324 for type 2 diabetes mellitus; Mivelsiran for cerebral amyloid angiopathy, as well as in Phase 1 trial for Alzheimer's disease; and ALN-6400 for bleeding disorders. Further, it develops a range of products in Phase 1 trial, such as ALN-2232 for obesity and weight management; ALN-PNP for non-alcoholic fatty liver disease; ALN-APOC3 for dyslipidemia; ALN-CIDEB for metabolic dysfunction-associated steatohepatitis; ALN-HTT02 for Huntington's disease; ALN-5288 for Alzheimer's disease; ALN-SOD for SOD1 amyotrophic lateral sclerosis; ALN-SNCA for Parkinson's disease; AG-236 for polycythemia vera; ALN-CFB for paroxysmal nocturnal hemoglobinuria; ALN-BCAT for hepatocellular carcinoma; and ALN-4285, ALN-4915, and ALN-F1202 for healthy volunteers. The company has collaborations with Regeneron Pharmaceuticals, Inc.; Roche Holding AG; Sanofi S.A.; Novartis AG; PeptiDream, Inc; Dicerna Pharmaceuticals, Inc.; and Ionis Pharmaceuticals, Inc. Alnylam Pharmaceuticals, Inc. was founded in 2002 and is headquartered in Cambridge, Massachusetts. |
| Long Name | Alnylam Pharmaceuticals, Inc. |
| Market | us_market |
| Market Cap | 37,361,491,968 |
| Market State | REGULAR |
| Max Age | 86,400 |
| Message Board Id | finmb_2796659 |
| Most Recent Quarter | 1,774,915,200 |
| Net Income To Common | 537,988,992 |
| Next Fiscal Year End | 1,798,675,200 |
| Non Diluted Market Cap | 38,459,631,778 |
| Number Of Analyst Opinions | 24 |
| Open | 283.59 |
| Operating Cashflow | 714,896,000 |
| Operating Margins | 0.23016001 |
| Overall Risk | 4 |
| Payout Ratio | 0.0 |
| Peg Ratio | 0.54 |
| Phone | 617 551 8200 |
| Previous Close | 288.06 |
| Price Eps Current Year | 29.855085 |
| Price Hint | 2 |
| Price To Book | 34.72329 |
| Price To Sales Trailing12 Months | 8.715223 |
| Profit Margins | 0.12550001 |
| Quick Ratio | 2.885 |
| Quote Source Name | Nasdaq Real Time Price |
| Quote Type | EQUITY |
| Recommendation Key | buy |
| Recommendation Mean | 1.75 |
| Region | US |
| Regular Market Change | -8.225006 |
| Regular Market Change Percent | -2.85531 |
| Regular Market Day High | 286.755 |
| Regular Market Day Low | 279.49 |
| Regular Market Day Range | 279.49 - 286.755 |
| Regular Market Open | 283.59 |
| Regular Market Previous Close | 288.06 |
| Regular Market Price | 279.835 |
| Regular Market Time | 1,784,037,817 |
| Regular Market Volume | 130,831 |
| Return On Assets | 0.10062 |
| Return On Equity | 0.90356004 |
| Revenue Growth | 0.964 |
| Revenue Per Share | 32.524 |
| Sand P52 Week Change | 0.20365608 |
| Sector | Healthcare |
| Sector Disp | Healthcare |
| Sector Key | healthcare |
| Share Holder Rights Risk | 6 |
| Shares Outstanding | 133,512,573 |
| Shares Percent Shares Out | 0.0434 |
| Shares Short | 5,799,788 |
| Shares Short Previous Month Date | 1,780,012,800 |
| Shares Short Prior Month | 5,300,015 |
| Short Name | Alnylam Pharmaceuticals, Inc. |
| Short Percent Of Float | 0.0579 |
| Short Ratio | 4.56 |
| Source Interval | 15 |
| State | MA |
| Symbol | ALNY |
| Target High Price | 550.0 |
| Target Low Price | 310.0 |
| Target Mean Price | 437.41666 |
| Target Median Price | 436.5 |
| Total Cash | 3,009,222,912 |
| Total Cash Per Share | 22.539 |
| Total Debt | 2,970,230,016 |
| Total Revenue | 4,286,923,008 |
| Tradeable | 0 |
| Trailing Annual Dividend Rate | 0.0 |
| Trailing Annual Dividend Yield | 0.0 |
| Trailing Eps | 3.98 |
| Trailing P E | 70.3103 |
| Trailing Peg Ratio | 0.5225 |
| Triggerable | 1 |
| Two Hundred Day Average | 362.55765 |
| Two Hundred Day Average Change | -82.72266 |
| Two Hundred Day Average Change Percent | -0.22816415 |
| Type Disp | Equity |
| Volume | 130,831 |
| Website | https://www.alnylam.com |
| Zip | 2,142 |